Skip to main content
. 2013 Sep 12;8(9):e73993. doi: 10.1371/journal.pone.0073993

Figure 2. Expression of BMP7 in MCL lymphoma cells.

Figure 2

Figure 2A: from patients tested by DNA chips, RT-PCR was performed in two independent experiments before therapy (lane 1, 3, 5, 7 and 9) and after therapy (lane 2, 4, 6, 8 and 10). Patient 1 (lanes 1 and 2), patient 2 (lanes 3 and 4), patient 3 (lanes 5 and 6), patient 4 (lane7 and 8) patient 5 (lanes 9 and 10). Patients 1, 2 and 4 were initially sensitive to chemotherapy (secondary resistant tumors). Human placenta was used as a positive control (lane 11) and mix without cDNA as negative control (lane 12). BMP7 was expressed in the 3 patients at relapse, but was not expressed in the 2 patients with refractory disease at diagnosis and after having failed on therapy. ß2microglobuline probe was used as internal reference. Figure 2B: Immunohistochemical analysis of one of the 2 patient’s tumor at diagnosis and at relapse, that expressed BMP7 at relapse (secondary resistant lymphoma).